(2S,4R)-4-[[[[2-[[叔丁氧羰基]氨基]乙基]氨基]羰基]氧基]-1,2-吡咯烷二甲酸 1-(9H-芴-9-基甲基)酯结构式
|
常用名 | (2S,4R)-4-[[[[2-[[叔丁氧羰基]氨基]乙基]氨基]羰基]氧基]-1,2-吡咯烷二甲酸 1-(9H-芴-9-基甲基)酯 | 英文名 | Fmoc-Hyp(Bom)-OH |
---|---|---|---|---|
CAS号 | 187223-15-0 | 分子量 | 539.577 | |
密度 | 1.35±0.1 g/cm3 | 沸点 | 749.0±60.0 °C at 760 mmHg | |
分子式 | C28H33N3O8 | 熔点 | N/A | |
MSDS | N/A | 闪点 | 406.8±32.9 °C |
用途Fmoc Hyp(Bom)-OH是一种不可切割的ADC连接物,用于合成抗体药物结合物(ADC)。Fmoc Hyp(Bom)-OH也是一种基于烷基链的PROTAC连接剂,可用于合成PROTAC[1]< |
中文名 | (2S,4R)-4-[[[[2-[[叔丁氧羰基]氨基]乙基]氨基]羰基]氧基]-1,2-吡咯烷二甲酸 1-(9H-芴-9-基甲基)酯 |
---|---|
英文名 | fmoc-l-hyp(bom)-oh |
英文别名 | 更多 |
描述 | Fmoc Hyp(Bom)-OH是一种不可切割的ADC连接物,用于合成抗体药物结合物(ADC)。Fmoc Hyp(Bom)-OH也是一种基于烷基链的PROTAC连接剂,可用于合成PROTAC[1]< |
---|---|
相关类别 | |
靶点 |
Cleavable |
体外研究 | ADC由抗体组成,抗体通过ADC连接体连接ADC细胞毒素[1]。PROTAC包含两个不同的配体,通过连接体连接;一个是E3泛素连接酶的配体,另一个是靶蛋白的配体。PROTAC利用细胞内泛素-蛋白酶体系统选择性降解目标蛋白质[2]。 |
参考文献 |
密度 | 1.35±0.1 g/cm3 |
---|---|
沸点 | 749.0±60.0 °C at 760 mmHg |
分子式 | C28H33N3O8 |
分子量 | 539.577 |
闪点 | 406.8±32.9 °C |
精确质量 | 539.226746 |
PSA | 143.50000 |
LogP | 3.54 |
蒸汽压 | 0.0±2.6 mmHg at 25°C |
折射率 | 1.620 |
储存条件 | 2-8°C,干燥密封 |
水溶解性 | Insuluble (1.5E-3 g/L) (25 ºC) |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:NOVARTIS AG; NOVARTIS PHARMA GMBH Patent: WO2004/52817 A1, 2004 ; Location in patent: Page 19-20 ; |
~70% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
~% (2S,4R)-4-[[[[2... 187223-15-0 |
文献:Lewis, Ian; Bauer, Wilfried; Albert, Rainer; Chandramouli, Nagarajan; Pless, Janos; Weckbecker, Gisbert; Bruns, Christian Journal of Medicinal Chemistry, 2003 , vol. 46, # 12 p. 2334 - 2344 |
1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylmethyl) ester, (2S,4R)- |
1-[(9H-Fluoren-9-ylmethoxy)carbonyl]-4-({[2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)ethyl]carbamoyl}oxy)proline |
Fmoc-(2S,4R)-Pro(4-OCO-NH-CH2-CH2-NH-Boc)-OH |
1,2-Pyrrolidinedicarboxylic acid, 4-[[[[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-, 1-(9H-fluoren-9-ylmethyl) ester |
(4R)-1-[(9H-Fluoren-9-ylmethoxy)carbonyl]-4-({[2-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)ethyl]carbamoyl}oxy)-L-proline |
Fmoc-Hyp(Bcc)-OH |
Fmoc-(2S,4R)-(4-OCO-NH-CH2-CH2-NH-Boc)-Pro-OH |
(2S,4R)-4-[[[[2-[[(1,1-Dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]oxy]-1,2-pyrrolidinedicarboxylic acid 1-(9H-fluoren-9-ylmethyl) ester |
Fmoc-Hyp(Bom)-OH |